SCHEMBL4237656

SCHEMBL4237656

CCCCN1CCC(Oc2ccc(C(=O)Nc3ccc(Oc4ccc(N)cc4OC)cc3F)cc2C)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR4 Q13639 4/20 0.44
ACHE P22303 1/20 0.43
PDE4D Q08499 2/20 0.42
FGFR1 P11362 2/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
POLB P06746 1/20 0.40
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
ADRA2C P18825 1/20 0.39
CHRM3 P20309 1/20 0.39
HTR1D P28221 1/20 0.39
ADRA1B P35368 1/20 0.39
HTR2B P41595 1/20 0.39
HTR3A P46098 1/20 0.39
HRH3 Q9Y5N1 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
GRM7 Q14831 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4236608 0.93 FGFR1 (0.46) HTR4ACHEPDE4DFGFR1CYP1A2
SCHEMBL4236294 0.89 HTR4 (0.45) HTR4PDE4DCYP3A4CYP2C19POLB
SCHEMBL4237553 0.89 WDR5 (0.45) HTR4PDE4DPOLBMEN1KMT2A
SCHEMBL4238603 0.88 HTR4 (0.42) HTR4PDE4DCHRM4CHRM5ADRA2C
SCHEMBL4371223 0.88 HTR4 (0.45) HTR4ACHEPDE4DCHRM3MEN1
SCHEMBL4238135 0.86 SMN1; SMN2 (0.41) HTR4PDE4DFGFR1CYP1A2CYP3A4
SCHEMBL4684563 0.84 KDR (0.44) PDE4DHRH3
SCHEMBL4238014 0.83 PKM (0.40) HTR4PDE4DHRH3
SCHEMBL4236414 0.83 MAPT (0.46) PDE4DCYP1A2POLBHRH3MEN1
SCHEMBL4233934 0.83 MAPT (0.47) HTR4FGFR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R HTR4 102/4885ACHE 560/4885PDE4D 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.